Ilyang shares boosted by new leukemia drug

Published: 2012-01-11 06:57:00

Updated: 2012-01-11 06:57:00

Shares of Ilyang Pharmaceutical Co., a Korean drug developer, were boosted on Monday by expectations that its new leukemia treatment may help lift earnings in the second half of this year, analyst said.

Ilyang shares rose 12 percent to 41,950 won in the morning of Monday on the Seoul bourse, s...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK